Literature DB >> 2479674

Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies.

B E Sundström1, W B Nathrath, T I Stigbrand.   

Abstract

The cytokeratins 8, 18, and 19, expressed in many normal and malignant epithelial cells, were purified from human gastrointestinal tumors and used as immunogen for hybridoma generation. The reactivity pattern of five of the generated ten monoclonal antibodies (MAb) was characterized biochemically and immunohistochemically. All of the generated MAb were reactive with the central rod portion of the cytokeratins, as determined after partial enzymatic degradation, and displayed characteristic reactivity patterns. MAb TS 4 exhibits pan-epithelial immunohistochemical reactivity staining of all epithelial structures, including all layers of epidermis and non-keratinizing squamous epithelium and myoepithelial cells. The determinant involved is present on several different cytokeratins, i.e., nos. 1, 5, 7, 8, and 15, as determined by immunoblotting experiments from different tissues and cell lines. MAb TS 1, TS 3, and TS 7 reveal pluri-epithelial reactivity pattern immunohistochemically, similar to TS 4, but they are unreactive with whole epidermis and with superficial cell layers of non-keratinizing squamous cells. MAb TS 1 was found to be highly specific and reactive only with cytokeratin 8. Furthermore, the TS 1 MAb alone can precipitate the antigen, indicating reactivity with repetitive epitopes on cytokeratin 8. MAb TS 3 and 7 bind to cytokeratins 7 and 8. Finally, MAb TS 8 was found to be immunohistologically the most restricted, in general lacking reactivity to hepatocytes, pancreatic and salivary gland acinar cells, proximal renal tubules, and luminal cells of the epididymis. TS 8 was mainly reactive with cytokeratin 19 and showed weak binding to cytokeratin 8 and 14.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479674     DOI: 10.1177/37.12.2479674

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

1.  Functional mapping of the anti-idiotypic antibody anti-TS1 scFv using site-directed mutagenesis and kinetic analysis.

Authors:  Ann Erlandsson; Patrik Holm; Rozbeh Jafari; Torgny Stigbrand; Birgitta E Sundström
Journal:  MAbs       Date:  2010 Nov-Dec       Impact factor: 5.857

2.  Regional variations in the expression of cytokeratin proteins in the adult human cochlea.

Authors:  M Anniko; W Arnold; L E Thornell; I Virtanen; F C Ramaekers; C R Pfaltz
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

3.  Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours.

Authors:  David Eriksson; Homa Mirzaie Joniani; Ali Sheikholvaezin; Per-Olov Löfroth; Lennart Johansson; Katrine Riklund Ahlström; Torgny Stigbrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

4.  Correlation of beta-camera imaging and immunohistochemistry in radioimmunotherapy using 90Y-labeled monoclonal antibodies in ovarian cancer animal models.

Authors:  K J Kairemo; K Ljunggren; T Wahlström; T Stigbrand; S E Strand
Journal:  Cell Biophys       Date:  1994

5.  Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.

Authors:  A Ullén; K Riklund Ahlström; R Makiya; T Stigbrand
Journal:  Cell Biophys       Date:  1995-08

6.  Optimization of production of the anti-keratin 8 single-chain Fv TS1-218 in Pichia pastoris using design of experiments.

Authors:  Rozbeh Jafari; Birgitta E Sundström; Patrik Holm
Journal:  Microb Cell Fact       Date:  2011-05-16       Impact factor: 5.328

7.  Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice.

Authors:  Ann Erlandsson; Eva Forssell-Aronsson; Tomas Seidal; Peter Bernhardt
Journal:  EJNMMI Res       Date:  2011-08-26       Impact factor: 3.138

8.  Clinical significance of serum CYFRA 21-1 in gastric cancer.

Authors:  B Nakata; Y S Chung; Y Kato; M Ogawa; Y Ogawa; A Inui; K Maeda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.